NervGen Pharma released its earnings results on Aug 22, 2024. The company reported -$0.081 earnings per share for the quarter, missing the consensus estimate of -$0.066 by -$0.015.

Is NervGen Pharma overvalued?

According to Wall Street analysts NervGen Pharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does NervGen Pharma pay dividends?

NervGen Pharma does not currently pay dividends.

What is NervGen Pharma’s EPS estimate?

NervGen Pharma’s EPS estimate is -$0.07.

How many shares outstanding does NervGen Pharma have?

NervGen Pharma has 70,180,145 shares outstanding.

What happened to NervGen Pharma’s price movement after its last earnings report?

NervGen Pharma reported an EPS of -$0.081 in its last earnings report, missing expectations of -$0.066. Following the earnings report the stock price went down -0.952%.

Which hedge fund is a major shareholder of NervGen Pharma?

Currently, no hedge funds are holding shares in NGENF

---

NervGen Pharma Stock Smart Score

Unlock Smart Score

Fundamentals

Return on Equity

-228.94%

Trailing 12-Months

Asset Growth

54.86%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

NervGen Pharma

NervGen Pharma Corp is a regenerative medicine company dedicated to creating solutions for the treatment of nerve damage and neurodegenerative diseases. The company's lead compound, NVG-291, has placed ahead for both spinal cord injury and multiple sclerosis. The company plans to initiate a Phase 1 human clinical trial on healthy subjects in early 2020 with an expansion of the trial in the second half of 2020 to include a cohort of spinal cord injury patients. In addition, the company intends to commence a Phase 2 multiple sclerosis clinical trial in early 2021.

---

NGENF Stock 12 Month Forecast

Average Price Target

$2.57

▲(28.13% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","3":"$3","0.75":"$0.75","1.5":"$1.5","2.25":"$2.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2.93456292,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.93</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.57,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.20092219,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.20</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,0.75,1.5,2.25,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2024","6":"Apr<br/>2024","9":"Jun<br/>2024","12":"Sep<br/>2024","25":"Sep<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.94,2.01650484,2.0930096799999998,2.16951452,2.24601936,2.3225242,2.39902904,2.47553388,2.5520387199999996,2.62854356,2.7050484,2.78155324,2.8580580799999997,{"y":2.93456292,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.94,1.9884615384615385,2.036923076923077,2.085384615384615,2.1338461538461537,2.1823076923076923,2.230769230769231,2.279230769230769,2.3276923076923075,2.376153846153846,2.4246153846153846,2.473076923076923,2.5215384615384613,{"y":2.57,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.94,1.9600709376923076,1.9801418753846154,2.000212813076923,2.020283750769231,2.0403546884615382,2.060425626153846,2.080496563846154,2.1005675015384617,2.120638439230769,2.140709376923077,2.160780314615385,2.180851252307692,{"y":2.20092219,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.38,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.36,"date":1698796800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.3,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.85,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.18,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.5,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.6,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.48,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.7,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.46,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.36,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.03,"date":1722556800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.94,"date":1725580800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >

Technical Analysis

Similar Stocks

NRX Pharmaceuticals

―

INMB

Inmune Bio

―

SAVA

Cassava Sciences

―

AVXL

Anavex Life Sciences

―

Compare NGENF Stocks >

Best Analysts Covering NGENF

1 Year

Justin KeywoodStifel Nicolaus

1 Year Success Rate

3/4 ratings generated profit

1 Year Average Return

+7.07%

assigned a buy rating 28 days ago

Copying Justin Keywood's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +7.07% per trade.

Best Analyst Covering >

Popular Stocks

---

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

NervGen Pharma (NGENF) Stock Price & Analysis

NGENF Stock Chart & Stats

NervGen Pharma News

Financials

Options Prices

Ownership Overview

NGENF FAQ

NervGen Pharma Stock Smart Score

Analyst Consensus

News Sentiment

Technicals

Fundamentals

Company Description

NervGen Pharma

NGENF Stock 12 Month Forecast

Average Price Target

Technical Analysis

Best Analysts Covering NGENF

Become an Expert with TipRanks Premium